Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Rhoda Molife"'
Autor:
Bedke, Jens, Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dimitry, Pouliot, Frederic, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J., Borchiellini, Delphine, McDermott, Raymond S., Tamada, Satoshi, Nguyen, Allison Martin, Wan, Shuyan, Perini, Rodolfo F., Rhoda Molife, L., Atkins, Michael B., Powles, Thomas
Publikováno v:
In European Urology October 2022 82(4):427-439
Autor:
Udai Banerji, Johann S. de Bono, Stanley B. Kaye, L. Rhoda Molife, Timothy A. Yap, Marta Capelan, Karim Rihawi, Begona Jimenez, Elena Geuna, Desamparados Roda, Saeed Rafii
Supplementary Figure 1. Occurence of infection during treatment with single agent PI3K-AKT-mTOR inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd5442bc5f5e5b565285c420f7464091
https://doi.org/10.1158/1078-0432.22454603
https://doi.org/10.1158/1078-0432.22454603
Autor:
Johann S. de Bono, Bernd Hentsch, Vera Strobel, Bernhard Hauns, Anna Mais, Muyibat Olaleye, Isabel Casamayor, Ann Parker, Rebecca Kristeleit, L. Rhoda Molife, David Olmos, Rohit Lal, Joo Ern Ang, André T. Brunetto
Supplementary figure 1. Plot of resminostat concentration versus degree of HDAC enzyme inhibition at 2 hour post-dose on day 1 for all dose levels using the Hill model.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39630264a00477f0eaf1ad5fce361f3e
https://doi.org/10.1158/1078-0432.22449708
https://doi.org/10.1158/1078-0432.22449708
Autor:
Udai Banerji, Johann S. de Bono, Stanley B. Kaye, L. Rhoda Molife, Timothy A. Yap, Marta Capelan, Karim Rihawi, Begona Jimenez, Elena Geuna, Desamparados Roda, Saeed Rafii
Purpose: Novel antitumor therapies against the PI3K–AKT–mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these agents are not known to be myelosu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::320b7e42897e6d957e72f275be463ae7
https://doi.org/10.1158/1078-0432.c.6522800
https://doi.org/10.1158/1078-0432.c.6522800
Autor:
Johann S. de Bono, Bernd Hentsch, Vera Strobel, Bernhard Hauns, Anna Mais, Muyibat Olaleye, Isabel Casamayor, Ann Parker, Rebecca Kristeleit, L. Rhoda Molife, David Olmos, Rohit Lal, Joo Ern Ang, André T. Brunetto
Purpose: This first-in-human dose-escalating trial investigated the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and pharmacodynamics of the novel histone deacetylase (HDAC) inhibitor resminost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ccd977a53f75aaff9fa343237ed1641
https://doi.org/10.1158/1078-0432.c.6521730
https://doi.org/10.1158/1078-0432.c.6521730
Autor:
Michael B. Atkins, Dmitry Nosov, Lina Yin, L Rhoda Molife, Thomas Powles, Sergio J Azevedo, Jens Bedke, Satoshi Tamada, Elizabeth R. Plimack, Rustem Gafanov, Brian I. Rini, Delphine Borchiellini, Bohuslav Melichar, Denis Soulières, Ihor Vynnychenko, Mei Chen, Frédéric Pouliot, Viktor Stus, Raymond S. McDermott, T. Waddell
Publikováno v:
The Lancet Oncology. 21:1563-1573
The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b503bc50e2df9c7af2fcc5bc34fe4a3
https://doi.org/10.1016/s1470-2045(20)30436-8
https://doi.org/10.1016/s1470-2045(20)30436-8
Autor:
Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, Rustem Gafanov, Tom Waddell, Dimitry Nosov, Frederic Pouliot, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Sergio J. Azevedo, Delphine Borchiellini, Raymond S. McDermott, Satoshi Tamada, Allison Martin Nguyen, Shuyan Wan, Rodolfo F. Perini, L. Rhoda Molife, Michael B. Atkins, Thomas Powles
Publikováno v:
European urology. 82(4)
In the phase 3 KEYNOTE-426 (NCT02853331) trial, pembrolizumab + axitinib demonstrated improvement in overall survival, progression-free survival, and objective response rate over sunitinib monotherapy for advanced renal cell carcinoma (RCC).To evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9723e0ee94f90feee8cda326ca0ef342
https://pubmed.ncbi.nlm.nih.gov/36175267
https://pubmed.ncbi.nlm.nih.gov/36175267
Autor:
Plimack, Elizabeth R., Powles, Thomas, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Waddell, Tom, Alekseev, Boris, Pouliot, Frédéric, Melichar, Bohuslav, Soulières, Denis, Borchiellini, Delphine, McDermott, Raymond S., Vynnychenko, Ihor, Chang, Yen-Hwa, Tamada, Satoshi, Atkins, Michael B., Li, Chenxiang, Perini, Rodolfo, Rhoda Molife, L., Bedke, Jens, Rini, Brian I.
Publikováno v:
In European Urology November 2023 84(5):e123-e124
Autor:
Christian Rolfo, L Rhoda Molife, Jean-Yves Blay, Alain Ravaud, Katerina Kopeckova, Rebecca Kristeleit, Antoine Italiano, Jan H.M. Schellens, Nicolas Isambert, Judith de Vos-Geelen, Wendy Bannister, Regina Demlová, Maria Learoyd, Myung-Ah Lee, Gershon Y. Locker, Olivier Rosmorduc, Thomas Decaens
Publikováno v:
British Journal of Clinical Pharmacology, 86(9), 1807-1818. Wiley
Br J Clin Pharmacol
Br J Clin Pharmacol
Aims Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially hepatically cleared. We investigated the pharmacokinetics (PK) and safety of olaparib in patients with mild or moderate hepatic impairment to provide dosing recommendati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f8942641984e913e81ebca1eb66171e
https://cris.maastrichtuniversity.nl/en/publications/3f6c882d-a88f-4c5a-92ca-fde001eb9f0b
https://cris.maastrichtuniversity.nl/en/publications/3f6c882d-a88f-4c5a-92ca-fde001eb9f0b
Autor:
Geraldine Perkins, Timothy A Yap, Lorna Pope, Amy M Cassidy, Juliet P Dukes, Ruth Riisnaes, Christophe Massard, Philippe A Cassier, Susana Miranda, Jeremy Clark, Katie A Denholm, Khin Thway, David Gonzalez De Castro, Gerhardt Attard, L Rhoda Molife, Stan B Kaye, Udai Banerji, Johann S de Bono
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e47020 (2012)
Tumor genomic instability and selective treatment pressures result in clonal disease evolution; molecular stratification for molecularly targeted drug administration requires repeated access to tumor DNA. We hypothesized that circulating plasma DNA (
Externí odkaz:
https://doaj.org/article/3dec2081d85c4d8ca5a5e0e4c2fc16a1